showme
Prominent proteins in cancer
This is the list of significantly mutated genes (SMGs) and other proteins significantly involved in edgetic perturbations in STES.
Perturbation typeGeneCitationCancer typeGene-disease relation
Top gainsANK1 (Isoform switch)22603795Barret esophagusDifferentially expressed in Barrett esopjhagus patients compared to expression profiles in heathy controls
Top gainsTTN (Isoform switch)29101304ESCClncRNA-TTN-AS1 is significantly associated with overall survival and provides additional prognostic evidence for esophageal squamous cell carcinoma (ESCC) patients
Top lossesCEP170B (Isoform switch)22603795Barret esophagusDifferentially expressed in Barrett esopjhagus patients compared to expression profiles in heathy controls
Top gainsCLEC5A22603795; 21445269Barret esophagus; Gastric cancerDifferentially expressed in tumor samples.
Top gainsHOXA921259057; 29113222Esophageal cancer; Gastric cancerDifferentially expressed in tumor samples.
Top gainsMAPK1530957200; 26035356ESCC; Gastric cancerMAPK15 mutation associated with ESCC. : Overexpression of MAPK15 in gastric cancer is associated with copy number gain
Top gainsSTAC322603795; 21445269Barret esophagus; Gastric cancerDifferentially expressed in tumor samples.
Top gainsTNFRSF928442363; 21684283ESCC; Gastric cancerDysregulated in ESCC. : Differentially expressed in gastric cancer.
Top gainsTNFSF1125019155; 29340518ESCC; Gastric cancerRANKL(TNFSF11) rs9533156 T>C is associated with a risk of ESCC. : Rankl (TNFSF11) expression predicts poor prognosis in gastric cancer patients
Top cancer-specific gainsSTAC322603795; 21445269Barret esophagus; Gastric cancerDifferentially expressed in tumor samples.
Top lossesADCYAP117636545; 10850463Barret esophagus; Gastric cancerDysregulaed in Barrett's adenocarcinoma. : Overexpression of PACAP(ADCYAP1) receptors has been reported in stomach cancer.
Top lossesAGTR127564102; 25224569ESCC; Gastric cancerAngiotensin II/AT1R signaling stimulates ESCC growth; in part through mTOR activation. : The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer.
Top lossesAPP15252842; 30686901ESCC; Gastric cancerThe majority of ESCCs also had increase in APP mRNA expression. : Amyloid-beta(APP) oligomerization is strongly associated with gastric mucosal atrophy.
Top lossesASB1622603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesBMX22603795; 25499959Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus. : BMX-ARHGAP fusion transcript is differentially expressed in gastric cancer.
Top lossesCAMK2B30956903; 25174603ESCC; Gastric cancerDifferentially expressed in esophageal cancer samples. : CaMKII promotes gastric cancer cell metastasis by NF‑kappaB and Akt‑mediated‑MMP‑9 production.
Top lossesCCT6B20955586; 11782383ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples .
Top lossesEID322603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesENPP623341893; 30948703ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top lossesESR223358850; 26503819ESCC; Gastric cancerESR2 SNPs associated with ESCC and gastric cancer.
Top lossesGPM6A20955586; 15875780ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top lossesHSPA1L17318615; 11782383ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top lossesPACRG22603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesRXRG29600044; 22901127ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top lossesINA22603795; 11782383Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesLURAP122603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesSCN2B22603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesSPIN2B20955586; 22735568ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top lossesTCEANC22603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesTRIM4622603795; 25731870Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus cancer samples. : TRIM46 polymorphism associated with gastric cancer.
Top lossesTRIM922603795; 11782383Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesTSSK322603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesUSHBP122603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesSPATA2422603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top lossesZNF39622603795; 22127425Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top cancer-specific lossesHSPA1L17318615; 11782383ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top cancer-specific lossesTCEANC22603795; 22735568Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top cancer-specific lossesSPIN2B20955586; 22735568ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top cancer-specific lossesEDA2R29796185; 22735568ESCC; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
Top cancer-specific lossesCCT6B22603795; 11782383Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
Top cancer-specific lossesUSP622603795Barret esophagusDifferentially expressed in barret esophagus samples.
Top cancer-specific lossesETFBKMT22603795; 15800983Barret esophagus; Gastric cancerDifferentially expressed in barret esophagus and gastric cancer samples.
SMGs within edgetic gains or lossesATR27839769; 28138034Esophageal cancer; Gastric cancerATR inhibitor demonstrates improved response to standard therapies for esophageal cancer. : An oral inhibitor of ATR induces synthetic lethality with ATM deficiency in gastric cancer cells.
SMGs within edgetic gains or lossesCDH127600761; 9537325Esophageal cancer; Familial gastric cancerDecreased expression of CDH1 in the cell membranes of cancer cells is associated with poor survival of patients with esophageal cancer.: Hereditary CDH1 mutation associated with gastric cancer.
SMGs within edgetic gains or lossesERBB329138285Esophageal cancer; Gastric cancerDifferentially expressed in esophageal and gastric cancer samples.
SMGs within edgetic gains or lossesFAT325151357; 30005210ESCC; Gastric cancerFAT3 mutation associated with ESCC. : MEF2C-AS1 or FENDRR down-regulation reduced FAT3; NTN1; LYVE1 gene expression and promoted aggressive tumor phenotypes.
SMGs within edgetic gains or lossesGRIN2A17922030; 11782383ESCC; Gastric cancerThe NMDAR2A promoter was methylated in all esophageal squamous cell carcinoma. : Differentially expressed in gastric cancer samples.

To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button